5 Key Takeaways

• 1

  A study presented at the 2025 ASCRS annual meeting evaluated cyclosporine solution 0.09% in patients with uncontrolled dry eye on cyclosporine 0.05%.

• 2

  Patients received cyclosporine 0.09% twice daily for 12 weeks, with evaluations at baseline, 4, 8, and 12 weeks.

• 3

  Significant improvements were observed in total corneal fluorescein staining and mSANDE scores across all age and sex subgroups.

• 4

  Ophthalmologists are advised to consider switching patients inadequately controlled on cyclosporine 0.05% to cyclosporine 0.09%.

• 5

  The study found unexpected significant improvements in symptoms and corneal staining as early as 4 weeks, regardless of patient demographics.